Drug intelligence / Profile preview

choriogonadotropin beta

Development stage: Discontinued
Lead developer: Ferring Pharmaceuticals
Modality: Recombinant Proteins and Enzymes
Administration: Subcutaneous, Intramuscular

Overview

FE 999302 (choriogonadotropin beta) is an investigational drug being studied as an add-on treatment to follitropin delta (Rekovelle) in women undergoing controlled ovarian stimulation for fertility treatment. It appears to be a form of human chorionic gonadotropin, which is used to trigger final follicular maturation and luteinisation after stimulation of follicular growth in fertility treatments.

Other names: recombinant hCGrhCG

Targets

LHCGR (Luteinizing hormone/choriogonadotropin receptor)

Beyond the preview

Go deeper on choriogonadotropin beta.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on choriogonadotropin beta.

Explore the full profile